124 related articles for article (PubMed ID: 19965677)
1. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Reijmers RM; Groen RW; Rozemuller H; Kuil A; de Haan-Kramer A; Csikós T; Martens AC; Spaargaren M; Pals ST
Blood; 2010 Jan; 115(3):601-4. PubMed ID: 19965677
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
3. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
5. Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma.
Reijmers RM; Spaargaren M; Pals ST
FEBS J; 2013 May; 280(10):2180-93. PubMed ID: 23419151
[TBL] [Abstract][Full Text] [Related]
6. MDA-MB-231 breast cancer cell viability, motility and matrix adhesion are regulated by a complex interplay of heparan sulfate, chondroitin-/dermatan sulfate and hyaluronan biosynthesis.
Viola M; Brüggemann K; Karousou E; Caon I; Caravà E; Vigetti D; Greve B; Stock C; De Luca G; Passi A; Götte M
Glycoconj J; 2017 Jun; 34(3):411-420. PubMed ID: 27744520
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1: a dynamic regulator of the myeloma microenvironment.
Sanderson RD; Yang Y
Clin Exp Metastasis; 2008; 25(2):149-59. PubMed ID: 18027090
[TBL] [Abstract][Full Text] [Related]
8. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
[TBL] [Abstract][Full Text] [Related]
9. Mutation in the heparan sulfate biosynthesis enzyme EXT1 influences growth factor signaling and fibroblast interactions with the extracellular matrix.
Osterholm C; Barczyk MM; Busse M; Grønning M; Reed RK; Kusche-Gullberg M
J Biol Chem; 2009 Dec; 284(50):34935-43. PubMed ID: 19850926
[TBL] [Abstract][Full Text] [Related]
10. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.
Baert L; Manfroi B; Quintero M; Chavarria O; Barbon PV; Clement E; Zeller A; Van Kuppevelt T; Sturm N; Moreaux J; Tveita A; Bogen B; McKee T; Huard B
Matrix Biol; 2023 Jun; 120():60-75. PubMed ID: 37201729
[TBL] [Abstract][Full Text] [Related]
11. Potential role for Ext1-dependent heparan sulfate in regulating P311 gene expression in A549 carcinoma cells.
Katta K; Sembajwe LF; Kusche-Gullberg M
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1472-1481. PubMed ID: 29580921
[TBL] [Abstract][Full Text] [Related]
12. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
Stewart MD; Ramani VC; Sanderson RD
J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
[TBL] [Abstract][Full Text] [Related]
13. Biosynthesis of heparan sulfate in EXT1-deficient cells.
Okada M; Nadanaka S; Shoji N; Tamura J; Kitagawa H
Biochem J; 2010 May; 428(3):463-71. PubMed ID: 20377530
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
15. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway.
Yu S; Lv H; Zhang H; Jiang Y; Hong Y; Xia R; Zhang Q; Ju W; Jiang L; Ou G; Zhang J; Wang S; Zhang J
Biochem Biophys Res Commun; 2017 Apr; 485(2):432-439. PubMed ID: 28209511
[TBL] [Abstract][Full Text] [Related]
16. Reduced Expression of EXTL2, a Member of the Exostosin (EXT) Family of Glycosyltransferases, in Human Embryonic Kidney 293 Cells Results in Longer Heparan Sulfate Chains.
Katta K; Imran T; Busse-Wicher M; Grønning M; Czajkowski S; Kusche-Gullberg M
J Biol Chem; 2015 May; 290(21):13168-77. PubMed ID: 25829497
[TBL] [Abstract][Full Text] [Related]
17. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
[TBL] [Abstract][Full Text] [Related]
18. Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.
Cheung PK; McCormick C; Crawford BE; Esko JD; Tufaro F; Duncan G
Am J Hum Genet; 2001 Jul; 69(1):55-66. PubMed ID: 11391482
[TBL] [Abstract][Full Text] [Related]
19. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis.
Purushothaman A; Uyama T; Kobayashi F; Yamada S; Sugahara K; Rapraeger AC; Sanderson RD
Blood; 2010 Mar; 115(12):2449-57. PubMed ID: 20097882
[TBL] [Abstract][Full Text] [Related]
20. Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments.
Delcommenne M; Klingemann HG
Hum Antibodies; 2012; 21(1-2):29-40. PubMed ID: 22885958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
